🔎 Trials Near Me

Dachaigh › Liomfoma Neo-Hodgkin › Ohio › Cleveland

Sgrùdaidhean clionaigeach Liomfoma Neo-Hodgkin ann an Cleveland, OH

Tha 13 sgrùdaidhean airson Liomfoma Neo-Hodgkin a’ lorg phàirtichean aig làraichean ann agus timcheall air Cleveland (taobh a-staigh mu 30 mìle). Fosglaidh sgrùdadh gus faicinn cò as urrainn pàirt a ghabhail agus mar a chuireas tu fios air an sgioba.

Teacsa sgrùdaidh oifigeil (Beurla)

A’ fastadh airson sgrùdadh an seo? Seall e aig mullach na duilleige seo — $99 airson 30 latha →

T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

A’ fastadhÌre 1/2
  • University Hospitals Seidman Cancer Center, Cleveland
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 1 Dàmh 2026 · NCT06343311

A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )

A’ fastadhÌre 1
  • Cleveland Clinic, Cleveland
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 22 Sult 2026 · NCT07101328

Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

A’ fastadhÌre 1
  • Case Comprehensive Cancer Center, University Hospitals Seidman Cancer Center, Cleveland
  • Case Comprehensive Cancer Center, Cleveland Clinic Foundation Taussig Cancer Institute, Cleveland
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 9 Sult 2026 · NCT07225439

A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.

A’ fastadhÌre 1
  • Clinical Trial Site, Cleveland
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 4 Sult 2026 · NCT06393738

Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma

A’ fastadhÌre 1/2
  • Cleveland Clinic, Cleveland
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 25 Lùna 2026 · NCT05826535

A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

A’ fastadhÌre 3
  • Cleveland Clinical Taussig Cancer Center, Cleveland
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 4 Lùna 2026 · NCT07188558

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

A’ fastadhSgrùdadh amharc
  • University Hospitals Case Medical Center, Cleveland
  • Cleveland Clinic, Cleveland
Gach aois · Gach gnè · Air ùrachadh 6 Iuch 2026 · NCT01351545

Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab

A’ fastadhÌre 1
  • Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland
Aoisean 18 gu 65 · Gach gnè · Air ùrachadh 25 Ògmh 2026 · NCT06447376

CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)

A’ fastadhÌre 1/2
  • Cleveland Clinic, Cleveland
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 16 Gibl 2026 · NCT03328078

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

A’ fastadhSgrùdadh amharc
  • Massive Bio SYNERGY-AI site, Mayfield Heights · 12 mìle air falbh
Gach aois · Gach gnè · Air ùrachadh 28 Dàmh 2025 · NCT03452774

A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies

A’ fastadhÌre 1
  • University Hospitals Cleveland Medical Center, Cleveland
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 2 Dàmh 2025 · NCT05780034

IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers

A’ fastadhÌre 1/2
  • University Hospitals Cleveland, Cleveland
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 3 Ògmh 2025 · NCT06119685

Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Non-Hodgkin Lymphoma

A’ fastadhÌre 1
  • University Hospitals Seidman Cancer Center, Cleveland
  • Taussig Cancer Institute | Cleveland Clinic, Cleveland
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 21 Dàmh 2024 · NCT05312801

Sgrùdaidhean Liomfoma Neo-Hodgkin ann am bailtean eile

Sgrùdaidhean eile ann an Cleveland

Bho ClinicalTrials.gov, dàta air a thogail 6 Dàmh 2026. Bidh gach sgrùdadh a’ suidheachadh a chuidi fhèin; bidh an sgioba sgrùdaidh a’ co-dhùnadh cò as urrainn pàirt a ghabhail.